Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key ...

Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative ...

Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from ...

Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with ...

The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive ...

You'll come for the hands-on tweaking and wealth of features, and quickly forgive some of the workflow issues when you hear ...

AVXL rated Hold: strong $131.7M cash runway, but blarcamesine’s upside hinges on clearer efficacy and FDA approval.

In adolescents, the most common adverse events (occurring in =5% of ML-004-treated adolescents and at least twice the rate of placebo) were headache (13.7% vs. 3.9%), somnolence (11.8% vs. 0%), nausea ...

At ASCO 2026, oral abstract presenters highlighted new and exciting central nervous system (CNS) tumour treatments.

First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALS TDP-43 pathology is present ...

Diets rich in sugars and fats are associated with metabolic disorders such as insulin resistance, chronic inflammation and ...